ALTIMMUNE, INC. Proceeds from Common Stock Issued
ALTIMMUNE, INC. (ALT) reported Proceeds from Common Stock Issued of $8.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-12
- ALTIMMUNE, INC. proceeds from issuance of common stock for the quarter ending 2026-06-30 was -$89.00K, a 100.24% decline year-over-year.
- ALTIMMUNE, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $8.74M, a 74.84% decline year-over-year.
- ALTIMMUNE, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $61.65M.
- ALTIMMUNE, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $39.81M.
- ALTIMMUNE, INC. proceeds from issuance of common stock for fiscal 2025 was $173.73M, a 1638.37% increase from fiscal 2024.
- ALTIMMUNE, INC. proceeds from issuance of common stock for fiscal 2024 was $9.99M, a 88.46% decline from fiscal 2023.
- ALTIMMUNE, INC. proceeds from issuance of common stock for fiscal 2023 was $86.60M, a 54.19% increase from fiscal 2022.
- ALTIMMUNE, INC. proceeds from issuance of common stock for fiscal 2022 was $56.17M, a 13.34% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 3 month as first filed | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $8.65M 10-Q · filed 2026-08-12 | $70.30M derived: sum of 3 quarters · filed 2026-08-12 | $110.11M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | $8.74M 10-Q · filed 2026-05-13 | $70.39M derived: sum of 2 quarters · filed 2026-05-13 | $110.20M derived: sum of 3 quarters · filed 2026-05-13 | $147.73M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | $61.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $101.46M derived: sum of 2 quarters · filed 2026-03-06 | $138.99M derived: sum of 3 quarters · filed 2026-08-12 | $173.73M 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | $39.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $77.34M derived: sum of 2 quarters · filed 2026-08-12 | $112.09M 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | $37.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $72.27M 10-Q · filed 2026-08-12 | $72.57M 10-Q · filed 2025-08-12 | ||||||
| 2025-03-31 | $34.75M 10-Q · filed 2026-05-13 | ||||||||
| 2024-12-31 | $9.99M 10-K · filed 2026-03-06 | ||||||||
| 2023-12-31 | $72.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $73.25M derived: sum of 2 quarters · filed 2025-02-27 | $86.60M 10-K · filed 2025-02-27 | ||||||
| 2023-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $13.86M 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | $13.35M 10-Q · filed 2024-08-08 | ||||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $31.83M derived: sum of 2 quarters · filed 2024-03-27 | $53.18M derived: sum of 3 quarters · filed 2024-03-27 | $56.17M 10-K · filed 2024-03-27 | |||||
| 2022-09-30 | $31.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $53.18M derived: sum of 2 quarters · filed 2023-11-07 | $56.17M 10-Q · filed 2023-11-07 | $68.63M derived: sum of 4 quarters · filed 2023-11-07 | |||||
| 2022-06-30 | $21.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $24.34M 10-Q · filed 2023-08-10 | $36.80M derived: sum of 3 quarters · filed 2023-08-10 | $36.80M derived: sum of 4 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | $2.99M 10-Q · filed 2023-05-11 | $15.45M derived: sum of 2 quarters · filed 2023-05-11 | $15.45M derived: sum of 3 quarters · filed 2023-05-11 | $33.63M derived: sum of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | $12.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $12.46M derived: sum of 2 quarters · filed 2023-02-28 | $30.64M derived: sum of 3 quarters · filed 2023-02-28 | $64.81M 10-K · filed 2023-02-28 | $64.82M 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $18.18M derived: sum of 2 quarters · filed 2022-11-10 | $52.36M 10-Q · filed 2022-11-10 | $52.36M 10-Q · filed 2021-11-09 | $74.90M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $18.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $52.36M 10-Q · filed 2022-08-11 | $52.36M 10-Q · filed 2021-08-10 | $74.90M derived: sum of 3 quarters · filed 2022-08-11 | $77.73M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $34.18M 10-Q · filed 2022-05-12 | $34.18M 10-Q · filed 2021-05-17 | $56.72M derived: sum of 2 quarters · filed 2022-05-12 | $59.55M derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | $22.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $25.38M derived: sum of 2 quarters · filed 2022-03-15 | $48.16M 10-K · filed 2022-03-15 | ||||||
| 2020-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $25.61M 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | $22.78M 10-Q · filed 2021-08-10 | ||||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $4.33M 10-K · filed 2020-03-27 | |||||||
| 2018-09-30 | $4.33M 10-Q · filed 2018-11-13 | ||||||||
| 2016-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $3.37M derived: sum of 2 quarters · filed 2017-03-14 | $3.78M derived: sum of 3 quarters · filed 2017-03-14 | $3.80M 10-K · filed 2017-03-14 | |||||
| 2016-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.75M derived: sum of 2 quarters · filed 2016-11-04 | $1.77M 10-Q · filed 2016-11-04 | $1.80M derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2016-06-30 | $412.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $436.19K 10-Q · filed 2016-08-04 | $465.72K derived: sum of 3 quarters · filed 2017-03-14 | $1.03M derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2016-03-31 | $23.24K 10-Q · filed 2016-05-09 | $52.77K derived: sum of 2 quarters · filed 2017-03-14 | $619.82K derived: sum of 3 quarters · filed 2017-03-14 | $912.04K derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2015-12-31 | $29.53K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $596.59K derived: sum of 2 quarters · filed 2017-03-14 | $888.80K derived: sum of 3 quarters · filed 2017-03-14 | $973.13K 10-K · filed 2017-03-14 | |||||
| 2015-09-30 | $567.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $859.27K derived: sum of 2 quarters · filed 2016-11-04 | $943.60K 10-Q · filed 2016-11-04 | $3.74M derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2015-06-30 | $292.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $376.55K 10-Q · filed 2016-08-04 | $3.18M derived: sum of 3 quarters · filed 2017-03-14 | $13.24M derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2015-03-31 | $84.33K 10-Q · filed 2016-05-09 | $2.89M derived: sum of 2 quarters · filed 2017-03-14 | $12.95M derived: sum of 3 quarters · filed 2017-03-14 | $15.51M derived: sum of 4 quarters · filed 2017-03-14 | |||||
| 2014-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $12.87M derived: sum of 2 quarters · filed 2017-03-14 | $15.42M derived: sum of 3 quarters · filed 2017-03-14 | $18.14M 10-K · filed 2017-03-14 | |||||
| 2014-09-30 | $10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $12.62M derived: sum of 2 quarters · filed 2015-11-06 | $15.34M 10-Q · filed 2015-11-06 | $15.29M derived: sum of 4 quarters · filed 2016-03-11 | |||||
| 2014-06-30 | $2.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $5.28M 10-Q · filed 2015-08-05 | $5.23M derived: sum of 3 quarters · filed 2016-03-11 | $7.48M derived: sum of 4 quarters · filed 2016-03-11 | |||||
| 2014-03-31 | $2.72M 10-Q · filed 2015-05-07 | $2.67M derived: sum of 2 quarters · filed 2016-03-11 | $4.93M derived: sum of 3 quarters · filed 2016-03-11 | $8.68M derived: sum of 4 quarters · filed 2016-03-11 | |||||
| 2013-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $2.21M derived: sum of 2 quarters · filed 2016-03-11 | $5.90M 10-K · filed 2014-03-11 | $6.02M 10-K · filed 2016-03-11 | |||||
| 2013-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $6.02M derived: sum of 2 quarters · filed 2014-11-06 | $6.07M 10-Q · filed 2014-11-06 | $6.07M derived: sum of 4 quarters · filed 2015-03-11 | |||||
| 2013-06-30 | $3.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $3.81M 10-Q · filed 2014-08-05 | $3.81M derived: sum of 3 quarters · filed 2015-03-11 | $3.81M derived: sum of 4 quarters · filed 2015-03-11 | |||||
| 2013-03-31 | $53.41K 10-Q · filed 2014-05-08 | $53.41K derived: sum of 2 quarters · filed 2015-03-11 | $53.41K derived: sum of 3 quarters · filed 2015-03-11 | ||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $1.00 derived: sum of 2 quarters · filed 2015-03-11 | $38.98K 10-K · filed 2015-03-11 | ||||||
| 2012-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $38.98K 10-Q · filed 2013-11-07 | |||||||
| 2012-06-30 | $38.98K 10-Q · filed 2013-08-08 | ||||||||
| 2011-12-31 | $5.86M 10-K · filed 2014-03-11 | ||||||||
| 2011-06-30 | $5.10M 10-K · filed 2014-03-11 | ||||||||
| 2011-03-31 | $82.48K 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |